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Abstract: Neuroinflammatory mechanisms with glial cell activation have been implicated in the 
pathogenic process of Alzheimer’s disease (AD). Activation of the NLRP3 inflammasome is an es-
sential component of the neuroinflammatory response. A role for NLRP3 activation in AD is sup-
ported by both in vitro and in vivo preclinical studies with little direct investigation of AD brain 
tissue. RNA expression of genes of three glial cell markers, HLA-DRA, AIF-1 and GFAP; the com-
ponents of the NLRP3 inflammasome NLRP3, ASC, and caspase-1; and downstream pre-inflamma-
tory cytokines IL-1 β and IL-18, were investigated in the temporal cortex of AD patients and age- 
and sex-matched controls. Protein expression of GFAP was also assessed. Increases in both mRNA 
and protein expression were observed for GFAP in AD. There were no significant changes in other 
NLRP3 activation markers between groups. Our results indicate the involvement of astrocyte acti-
vation in AD, particularly in more severe patients. We found no evidence for the specific involve-
ment of the NLRP3 inflammasome. 




Alzheimer’s disease (AD)—the most common form of dementia—is a major cause of 
disability and premature death among older people worldwide [1,2]. Impaired cognitive 
function, behavioral changes, and consequent lack of independence in AD patients, along 
with an increasing prevalence of AD, substantially challenges the public health system. 
Several hypotheses have been postulated to explain the pathogenesis of AD. The pathol-
ogy of AD is characterized by the appearance of two hallmarks: senile plaques (SP), 
formed by progressive pathological assemblies of the amyloid beta (Aβ) peptide and neu-
rofibrillary tangles (NFTs), which are comprised of hyperphosphorylated microtubule-
associated protein tau [3]. These pathological markers may be indicative of pathogenic 
processes contributing to neuronal damage and death, although no single theory is suffi-
cient in explaining the cause or causes of AD.  
Neuroinflammation has been proposed as a factor involved in the pathogenesis of 
AD [4]. Neuroinflammation refers to the inflammatory response in the central nervous 
system (CNS), of which microglia and astrocytes are the prominent cellular mediators [5]. 
It may be initiated acutely in response to cellular damage or the invasion of pathogenic 
microorganisms in the CNS, enabling the maintenance of neural homeostasis [5]. Never-
theless, the persistent activation of microglia and/or astrocytes can also lead to deleterious 
inflammatory reactions during chronic stimulation by infections or in response to uncon-
trolled immune triggers, such as Aβ and tau oligomers [6,7]. The inflammatory cascade 
may then drive further amyloidogenesis and tauopathy, accelerating the disruption of 
neuronal function [8–11]. 
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One potentially important component of this neuroinflammatory process is activa-
tion of the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome. Func-
tioning as sensors for multiple stimuli, inflammasomes are the determinant regulators of 
the innate immune reaction, resulting in the secretion of proinflammatory cytokines. Dif-
ferent inflammasomes respond to particular pathogenic agents. NLRP3 can be activated 
by a wide range of aggregated substances, including the proteinaceous deposits associ-
ated with several neurodegenerative disorders, by detecting the damage to internal mem-
branes [12]. The NLRP3 inflammasome is composed of three proteins: a cytosolic sensor 
molecule NLRP3; an apoptosis-associated speck-like protein containing a caspase-activat-
ing recruitment domain (ASC, coded by PYCARD gene); and an effector molecule, cyste-
ine protease pro-caspase-1 (CASP1) [13]. By assembling into a large speck-like structure, 
ASC provides the platform together with NLRP3 for activating pro-caspase-1 [14]. The 
subsequent production of active caspase-1 is responsible for the cleavage of pro-interleu-
kin-1β (pro-IL-1β) and pro- interleukin-18 (pro-IL-18) into their mature forms, which then 
trigger inflammatory responses by stimulating downstream cytokines and chemokine re-
ceptors [15]. A potentially important role for NLRP3 inflammasome activation is indicated 
in AD by emerging pre-clinical animal model and cell model studies [16]. These have 
shown that the acutely activated NLRP3 inflammasome can exacerbate amyloid and tau 
pathologies [17–19], while both the accumulation of Aβ and aggregation of tau have been 
found to result in NLRP3 inflammasome activation [20,21]. However, there is little sup-
porting data from human studies, other than controversial findings indicating unchanged 
mRNA and protein expression of NLRP3 in small studies of post-mortem AD brain tissue 
[22,23]. 
The aim of this study is to investigate evidence for NLRP3 inflammasome activation 
in AD using brain tissue collected at post mortem from moderately and severely affected 
AD subjects and neuropathologically unaffected control subjects. The brain region exam-
ined in this project is the temporal cortex, as it is particularly affected by underlying mo-
lecular pathologies in AD [24]. We determined relative gene expression of three glial cell 
markers: Major Histocompatibility Complex, Class II; DR Alpha (HLA-DRA); Allograft 
Inflammatory Factor 1 (AIF-1) and Glial Fibrillary Acidic Protein (GFAP); the components 
of the NLRP3 inflammasome, NLRP3, ASC, and caspase-1; and downstream pre-inflam-
matory cytokines IL-1 β and IL-18. We also assessed GFAP and caspase-1 protein expres-
sion. 
2. Results 
2.1. RNA and Protein Expression of GFAP Was Increased in Advanced AD 
Gene expression of GFAP as a marker for astrocyte activation was significantly asso-
ciated with subject groups. It was significantly elevated in advanced AD but not signifi-
cantly so in moderate AD (Figure 1).  
 
Figure 1. RNA expression of GFAP. Quantitative PCR analysis of GFAP expression relative to geo-
metric mean of GAPDH and RPL13A housekeeping genes expression. Significant elevation of GFAP 
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expression was observed in advanced AD (p < 0.001, 95% confidence interval= (0.85, 3.40)) but not 
in moderate AD (p = 0.557, 95% confidence interval = (−0.58, 1.97)). Control, n = 37; moderate AD, n 
= 39; advanced AD, n = 39. Data are presented as the mean ± SEM and analyzed by the one-way 
ANOVA test followed by the Dunnett post hoc test. *** p ≤ 0.001. 
Determination of GFAP protein showed this to be significantly increased above con-




Figure 2. Automated capillary electrophoresis immuno-quantification analysis of GFAP protein ex-
pression. (a) Results are shown as gel-like image views in left panel and electropherograms in the 
right panel, showing decreasing intensities of bands and decreasing peak areas in AD subgroups. 
(b) GFAP protein expression significantly increased in AD (M = 0.31, SD = 0.49) compared with 
control (M = 0.11, SD = 0.17) (t(112) = −2.02, p = 0.05). (c) Further analysis of GFAP protein expression 
in individual AD subgroups (one-way ANOVA, F(2, 112) = 1.83, p = 0.17). Control, n = 37; moderate 
AD, n = 39; advanced AD, n = 39. Data are presented as the mean ± SD. * p = 0.05. 
2.2. RNA Expression of AIF1 and HLA-DRA Was Unchanged in AD 
Gene expression of indicators of microglial activation, AIF1 (Figure 3a) and HLA-
DRA (Figure 3b), was not significantly associated with subject groups.  




Figure 3. RNA expression of AIF1 and HLA-DRA. There was no significant difference between sub-
ject groups of (a) AIF1 expression (one-way ANOVA, F(2, 112) = 1.98, p = 0.143) and (b) HLA-DRA 
expression (one-way ANOVA, F(2, 112) = 0.62, p = 0.54). Control, n = 37; moderate AD, n = 39; ad-
vanced AD, n = 39. Data are presented as the mean ± SEM. 
2.3 RNA and Protein Expression of NLRP3 Inflammasome Was Unchanged in AD 
Relative gene expression of the components of the NLRP3 inflammasome, IL1B and 
IL18 is shown in Figure 4. No significant change was observed in any of these mRNAs in 
AD or either AD subgroup.  
 
Figure 4. RNA expression of the components of the NLRP3 inflammasome and downstream pro-
inflammatory cytokines. Control, n = 37; moderate AD, n = 39; advanced AD, n = 39. Data are pre-
sented as the mean ± SEM. 
Due to the low sensitivity, only pro-caspase-1 protein was detected by capillary elec-
trophoresis immunoblotting. The protein level of pro-caspase-1 was unchanged between 
groups (Figure 5). 




Figure 5. Protein expression of caspase-1. The detected pro-caspase-1 level was unchanged between 
groups (one-way ANOVA, F(2, 50) = 1.91, p = 1.58). Control, n = 17; moderate AD, n = 17; advanced 
AD, n = 19. Data are presented as the mean ± SD. 
Both in the whole sample and within the AD group, no significant association of any 
gene expression measure with apolipoprotein E genotype or sex was apparent, except for 
IL1beta, which showed an increased expression in males (t(113) = −2.21, p = 0.03). 
Re-analysis of gene expression data including RIN as a covariate made essentially no 
difference to the results, with no significant findings from the NLRP3 components and 
consistently elevated expression of GFAP, other than the small increase in HLA-DRA ex-
pression in advanced AD showing significance (GLM-UniANOVA, F = 3.717, R2 = 0.133, p 
= 0.028).  
3. Discussion 
Although the pathological process in AD remains ill-defined, the evidence that in-
flammation plays a role is strong. The current findings demonstrating an increase above 
control values in GFAP mRNA and protein expression, particularly in subjects with ad-
vanced AD pathology, support this. Such increases in GFAP are fairly well established in 
the brain in AD and are consistent with an activation of astrocytes, an indication of in-
flammatory response [25–29]. Interestingly, recent studies all observed the strong correla-
tion between plasma GFAP and AD pathology, suggesting its role as an early marker of 
AD [30–32].  
The evidence for changes in microglia in the AD brain in this study was equivocal. 
Two markers of microglia have been chosen for study based on the previous AD human 
post-mortem research [33]. We found no increase in mRNA expression of AIF1, also 
known as ionized calcium-binding adapter molecule 1 (Iba1). This is a marker for both 
activated and resting microglia. A review of previous studies found that the change of 
AIF-1 expression is not consistently reported in AD tissue [33], with many reports finding 
no change, although very few studies involved mRNA analysis [34]. A more recent study 
of protein immunoreactivity in the temporal cortex in AD also found no increase in AIF-
1, again in the presence of an elevation of GFAP [35]. The other microglial marker we 
studied was HLA-DRA mRNA, coding for a component of the major histocompatibility 
complex II. This is considered to have more specificity for activated microglia than AIF-1 
and has been reported as generally elevated in AD and correlated with AD plaque stage 
and clinical dementia rating [33], although only one previous mRNA study, in hippocam-
pal tissue, was identified. We did not observe an unequivocal change in this marker, alt-
hough the small increase that was found did emerge as significant after correction for 
RNA integrity.  
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A mechanism implicated in the inflammation associated with several chronic disease 
processes is activation of the NLRP3 inflammasome. This has substantial evidence sup-
porting its involvement in AD, primarily from in vitro and animal model paradigms, as 
described in the introduction [17–19]. The NLRP3 inflammasome in the brain is primarily 
associated with microglia [36,37]; the evidence from this post-mortem study of a small 
change in HLA-DRA mRNA expression provides some support for activation of microglia 
in AD, albeit to a much lesser extent than for the astrocyte marker GFAP. Direct measures 
of mRNA for proteins comprising the NLRP3 inflammasome do not, however, provide 
any support for its activation in AD. We did not detect significant differences in other 
NLRP3 inflammasome activation markers, including NLRP3, PYCARD and CASP1, as 
well as the downstream pro-inflammatory cytokines IL1B and IL18, between AD and con-
trol. This is nevertheless consistent with other post-mortem studies that reported no 
change in mRNA and protein expression of NLRP3, as well as mRNA expression of PY-
CARD and CASP1 in AD [22,23,38] (Table 1). Heneka and colleagues found an elevation 
of caspase-1 protein in the AD brain, while the other two protein components of the 
NLRP3 inflammasome were not reported [17]. Based on this, caspase-1 protein expression 
was investigated in our cohort. Due to the low sensitivity to cleaved/activated caspase-1, 
only pro-caspase-1 was detected ,which showed no significant changes between groups, 
consistent with the mRNA expression (Figure 5). While another microarray study found 
no differences in IL1B expression in the frontal and occipital regions between AD and 
control [39] (Table 1), our investigation has a much larger sample size with both clinical 
and neurological confirmation.  
Table 1. Gene and protein expression of the NLRP3 inflammasome in human post-mortem studies of Alzheimer’s disease. 
Study Sample Size Brain Region Technique 
Markers of NLRP3 Inflammasome 
NLRP3 PYCARD/ASC CASP1/Caspase-1 
Heneka et al. [17] 
AD, n = 12 
NC, n = 8 
FC 
HC WB NR NR  in AD 





















 in NC  
Liu et al. [23] AD, n = 5 







 in AD 
 in AD 
NR 
Li et al. [38] AD, n = 6-7 
NC, n = 6-7 
FC WB no change  in AD  in AD 
Present study AD, n = 78 
NC, n = 37 
TC qPCR no change no change no change 
Abbreviations: AD, Alzheimer’s disease; NC, non-demented control; FC, frontal cortex; EC, entorhinal cortex, HC, hippocampus; 
SFG, superior frontal gyrus; PCG, post-central gyrus; TC, temporal cortex; NR, not reported; WB, Western blot; qPCR, quantita-
tive real-time PCR.  denotes increased expression. 
The lack of concordance with findings from model systems is a concern; however, 
the profound differences in the time course of development of AD pathology in humans 
(years) compared to cellular (days) and animal (weeks-months) models may differentially 
influence the involvement of inflammatory processes. The gene expression profile of mi-
croglial activation in AD patients was distinct from existing mouse models [40], while glia 
can adopt a reactive nonphysiological phenotype in vitro, changing their gene expression 
features [41,42]. Thus, developing animal models that recapitulate multiple facets of AD 
and novel three-dimensional cell culture models are proposed to help us further under-
stand the role of inflammation in the progression of AD [4,43]. 
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There are inevitably many limitations to this post-mortem study. While we have a 
relatively substantial sample size in comparison to many such human brain studies, our 
results are limited to the one brain region investigated. It would be important in future 
studies to determine whether the astrocytic activation indicated by elevated GFAP mRNA 
is found in brain regions affected by AD other than the temporal cortex, particularly the 
hippocampus, and whether the absence of evidence for NLRP3 activation also extends to 
these other areas. Changes in the cellular expression of markers may not always be re-
flected by results in tissue due to recruitment or depletion of the relevant cell [44]. While 
the determination of mRNA can provide a direct measure of gene transcription, it may 
not always reflect the levels of, or changes in, translated protein end-product [45]. Fur-
thermore, the use of housekeeping genes to control for variability in mRNA yield and 
stability may be far from ideal, particularly in post-mortem human tissue that may be 
subject to a variety of factors, such as agonal state, postmortem interval, and brain pH, 
that influence and may severely compromise mRNA integrity [46,47]. Nevertheless, the 
use of samples from well-matched non-AD subjects provides some control for many of 
these confounding effects. 
4. Materials and Methods 
4.1. Source of Human Brain Tissue and Research Ethics Committee Approval  
Post-mortem brain tissue samples were obtained from the Manchester Brain Bank at 
Salford Royal NHS Foundation Trust (University of Manchester). The Manchester Brain 
Bank has been approved by the Newcastle & North Tyneside 1 Research Ethics Committee 
(REC reference 09/H0906/52+5).  
On the basis of the reported tau and Abeta amyloid pathology in each brain, samples 
of temporal cortical tissue from 37 control subjects (Braak Stage 0-II) and 39 each of mod-
erate (Braak Stage III-IV) and advanced AD (Braak Stage V-VI) subjects were studied. De-
mographic data and apolipoprotein E genotype for each group are listed in Table 2. Group 
differences in age were observed, and this variable was included as a covariate in gene 
expression analysis. 
Table 2. Demographic and clinical characteristics of study subjects. 
 Age of Death (Years) Post-Mortem Interval (Hours) 
APOE Genotype 
ε4 Non-Carrier ε4 Carrier 
Control group 
All (n = 37) 82.6 ± 11.5 81.2 ± 36.9 32 5 
Male (n = 19) 84.5 ± 9.4 85.7 ± 41.4 17 2 
Female (n = 18) 80.7 ± 13.3 76.5 ± 31.8 15 3 
Moderate AD group 
All (n = 39) 85.5 ± 6.3 79.4 ± 38.4 21 18 
Male (n = 20) 84.0 ± 6.5 81.2 ± 37.0 9 11 
Female (n = 19) 87.1 ± 6.0 77.5 ± 40.6 12 7 
Advanced AD group 
All (n = 39) 78.1 ± 8.8 * 86.2 ± 43.0 10 29 
Male (n = 20) 73.3 ± 4.7 * 82.7 ± 48.9 4 16 
Female (n = 19) 83.0 ± 9.3 89.6 ± 37.1 6 13 
* The age of death of the advanced AD group was younger than other two groups, but it was not correlated with any of the 
quantification values of mRNA or protein expression assessed in this study. 
Standard procedures were carried out, including post-mortem brain sample storage, 
handling, and examination according to UK research ethics. Unfixed samples were stored 
at −80 °C immediately after dissection until tissue homogenization. Research was con-
ducted in compliance with the principles of the Declaration of Helsinki.  
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4.2. Quantitative Real-Time PCR  
RNA expression was quantified using reverse transcriptase semi-quantitative real-
time PCR (RT-qPCR). All the procedures were performed according to the MIQE guide-
lines [48]. The MIQE checklist for this study is in Supplementary information (Table S1).  
4.2.1. RNA Isolation and cDNA Synthesis 
Total RNA extraction was performed using a TRIzol Reagent (Thermo Fisher, UK), 
followed by RNA clean up using a Monarch RNA Cleanup Kit (New England Biolabs, 
UK), according to the manufacturer’s instructions. RNA purity and concentrations were 
assessed using a NanoDrop 2100 (Thermo Fisher, UK). RNA concentrations ranged from 
184.8 to 593.5 ng/µL. An optical density at wavelength 260/280 nm range of 2.01–2.11 was 
chosen for this study. RNA integrity number (RIN) was assessed by an Agilent 2200 
TapeStation System. DNA contamination was assessed in RT-qPCR by using RNA with-
out reverse transcription step—cDNA synthesis. Single-stranded cDNA was synthesized 
from 1 ng of total RNA using M-MLV Reverse Transcriptase (ThermoFisher, UK). The 
cDNA concentrations were measured on a NanoDrop 2100 and diluted to 500 ng/µL in 
RNase-free water. 
4.2.2. Selection of Candidate Reference Genes and PCR Primer Design 
Six reference genes (RG) were selected for our cohort (Table S2) according to previous 
studies (Table S3). The stability of RGs was ranked by RefFinder [49], using the raw 
threshold cycle (Ct) value of RGs. All samples were run in triplicates, and the top two 
stable RGs—RPL13A and GAPDH—were chosen for delta Ct analysis (Figure S1).  
Primer pairs were designed by using Primer-BLAST (NCBI, 
http://www.ncbi.nlm.nih.gov/tools/ primer-blast/, accessed on 11th February 2019, and 
exon junctions were included wherever possible to avoid amplification of genomic DNA. 
Primer pairs with the least probabilities of amplifying nonspecific products as predicted 
by the NCBI PrimerBLAST were selected. Primers were synthesized by ThermoFisher. For 
each primer pair (Table S2), the optimal annealing temperature (Ta) was calculated using 
an online Tm Calculator (ThermoFisher) based on the modified Allawi & SantaLucia's 
thermodynamics method [50]. The amplification efficiency (E) and coefficient of correla-
tion (R2) were determined for each primer pair by at least 4 points on the standard curve. 
Primer specificity was analysed by dissociation curve (Figure S3). 
4.2.3. Reverse Transcriptase Semi-Quantitative Real-Time PCR (RT-qPCR) 
RT-qPCR reactions were carried out using Power SYBR Green PCR Master Mix 
(ThermoFisher, UK) on a 7900HT Real-Time PCR System with a 384-well format (Applied 
Biosystems, UK). The final volume for each reaction was 10 µL, with 1 µL (0.25 µM) of 
corresponding primers (Table S2), 1 µL (500 ng/µL) of total cDNA, 3 µL of RNase-free 
water, and 5 µL of SYBR green. A positive control (cDNA sample of control group which 
showed high Ct value of reference genes and a negative water control) was included for 
each primer pair on each plate. All samples were run in triplicates. The thermal cycler 
parameters were as follows: UDG activation at 50 °C for 2 minutes and DNA polymerase 
activation at 95 °C for 10 minutes, followed by amplification of cDNA for 40 cycles with 
denaturation at 95 °C for 15 seconds and annealing/extension at respective annealing tem-
perature for each gene (Table S2) for 1 minute. Dissociation curve analyses were carried 
out at the end of each run for PCR product verification (Figure S3). The intra-assay varia-
tion was controlled as standard deviation of triplicates < 0.2. The inter-assay variation was 
analysed by using raw the Ct value of RGs, and there was no significant variation between 
plates (Figure S2). 
  
Genes 2021, 12, 1753 9 of 12 
 
 
4.3. Protein Analyses: Capillary Electrophoresis Immunoblotting 
Protein expression of GFAP and caspase-1 was quantified using automated capillary 
electrophoresis immunoblotting. 
4.3.1. Protein Extraction and Purification 
A measurement of 40–60 mg of brain tissue was homogenized by a 10-fold volume 
(mg:µL) of lysis buffer (pH 7.4, 10 mM Trizma base, 2 mM EDTA, 320 µM sucrose (Sigma-
Aldrich, UK)). A cOmplete Protease Inhibitor Cocktail (Sigma-Aldrich, UK), phenylme-
thylsulfonyl fluoride (PMSF), and sodium orthovanadate were added to the lysis buffer 
immediately before use at 4%, 1%, and 1% (v/v) concentrations, respectively. The differ-
ential centrifugation method was used for protein purification [51]. 
4.3.2. Protein Quantification 
Automated capillary electrophoresis immuno-quantification was conducted on a 
Wes instrument for target protein analyses, according to the manufacturer's protocol (Pro-
teinSimple) [52]. In brief, protein concentration was assessed using the Bradford assay, 
then optimization of sample concentration and primary antibodies was carried out for 
each protein. The sample was diluted to the optimized concentration—0.4 mg/mL. After 
being mixed with a master mix containing dithiothreitol and a fluorescent molecular 
weight marker in a ratio of 5:1, samples were heated at 95 °C for 5 minutes for denatura-
tion. Then, prepared samples, blocking reagent (Wes antibody diluent), target protein pri-
mary antibodies, horseradish peroxidase (HRP)-conjugated secondary antibodies, and 
chemiluminescent substrate were loaded into the allocated wells of a Wes plate, which 
pre-loaded with sample and stacking matrices. Instrument default settings were used. The 
size-based separation electrophoresis, immobilization, and immunodetection were auto-
matically processed in the capillary array system, and the produced chemiluminescence 
was detected at multiple exposure times and quantified by the ProteinSimple v3.1 soft-
ware. The primary antibodies used were rabbit anti-GFAP (1:200, ab68428, Abcam, UK,) 
and recombinant anti-Caspase-1 (1:200, ab207802, Abcam, UK,). The total protein value 
detected by Total Protein assay (ProteinSimple) of each sample was used for normaliza-
tion.  
4.4. Statistical Analysis 
mRNA analysis was carried out using the 2(-Delta Delta Ct) Method [53]. Raw Ct 
values were normalized using the geometric mean of two RGs as an endogenous internal 
standard. For our cohort, the most stable RGs were RPL13A and GAPDH (Figure S1). Data 
are displayed as mean ± SD or mean ± SEM. Gaussian distribution was evaluated using 
the Shapiro-Wilk normality test. Homogeneity of variance was evaluated using Levene’s 
test. Statistical analyses were conducted in IBM SPSS Statistics 23 and GraphPad Prism 7 
software using non-paired parametric Student’s t-test, Welch’s t-test for unequal vari-
ances, one-way ANOVA followed bya post hoc test, and Pearson correlation or Spearman 
rank correlation. Statistical significance was set at p-value ≤ 0.05 (*p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001).  
5. Conclusions  
In conclusion, we find that while there is evidence for a substantial activation of as-
trocytes in the temporal cortex in late-stage AD, there is no apparent activation of the 
NLRP3 inflammasome, contrary to the findings in relatively acute model systems mim-
icking AD pathogenesis. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/genes12111753/s1: Figure S1: Reference gene stability rankings summarized by 
RefFinder, Figure S2: Anaylsis of inter-assay variation, Figure S3: Melting curves for all analyzed 
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candidate reference genes and the genes of interest, Table S1: MIQE checklist for the RT-qPCR ex-
periment, Table S2: Overview of genes and corresponding primer pairs for reverse transcriptase 
quantitative real-time PCR, Table S3: Summaries of reference gene stability in studies that assessed 
reference gene stability in the post-mortem brain of neurodegenerative diseases. 
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H.T.; validation, H.T. and M.H.; formal analysis, H.T. and M.H.; investigation, H.T.; resources, M.H.; 
data curation, H.T. and M.H.; writing—original draft preparation, H.T.; writing—review and edit-
ing, M.H.; visualization, H.T. and M.H.; supervision, M.H.; project administration, M.H.; funding 
acquisition, H.T. and M.H. All authors have read and agreed to the published version of the manu-
script. 
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